Business
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial o...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n\n\n\n\n Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n One of three patients in Cohort 5 achieved complete histological remission at 12 weeks.\n \n\n Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI\n \n 1\n \n ) scores at 12 weeks.\n \n\n At 24 weeks, the fourth cohort experienced the largest average reduction in SDI scores of all cohorts to date.\n \n\n The fifth cohort continued to show improved patient outcomes with the greatest percentage change in histology (EoEHSS\n \n 2\n \n ) scores of any cohort to date.\n \n\n Both the mean reduction in Peak Eosinophil Counts (PEC\n \n 3\n \n )at four biopsy sites and the percent change in histology (EoEHSS\n \n 2\n \n ) scores showed a clear dose response across Cohorts 3 to 5, with Cohort 5 showing the greatest response. No serious adverse events reported in any of the five cohorts to date.\n \n\n Cohort 6 is now fully enrolled and dosed, with 12-week data anticipated in Q1 2025.\n \n\n\n\n\n VICTORIA, BC\n \n\n ,\n \n\n Nov. 12, 2024\n \n\n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company developing precision drug delivery for indications with significant unmet need, today announced additional positive clinical data from its RESOLVE Phase\n \n 1b\n \n /2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (\"EoE\").\n \n\n\n\n\n\n\n\n\n\n\n New Clinical Data from the Fifth Cohort of the RESOLVE Trial\n \n\n\n\n The results announced today from the fifth cohort of the RESOLVE trial, for treatment of EoE, are derived from 12, 4 mg injections of EP-104GI (total dose of 48 mg) administered to the lower two-thirds of each patient's esophagus. The data show:\n \n\n\n One patient achieved...